Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 80

1.

A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial.

Blauvelt A, Papp K, Gottlieb A, Jarell A, Reich K, Maari C, Gordon KB, Ferris LK, Langley RG, Tada Y, Lima RG, Elmaraghy H, Gallo G, Renda L, Park SY, Burge R, Bagel J; IXORA-R Study Group.

Br J Dermatol. 2019 Dec 30. doi: 10.1111/bjd.18851. [Epub ahead of print]

PMID:
31887225
2.

Dupilumab drug survival, treatment failures, and insurance approval at a tertiary care center in the United States.

Khosravi H, Zhang S, Anderson AM, Ferris LK, Choudhary S, Patton T.

J Am Acad Dermatol. 2019 Dec 20. pii: S0190-9622(19)33311-0. doi: 10.1016/j.jaad.2019.12.034. [Epub ahead of print] No abstract available.

PMID:
31866263
3.

Corrigendum: Impact on clinical practice of a non-invasive gene expression melanoma rule-out test: 12-month followup of negative test results and utility data from a large US registry study.

Ferris LK, Rigel DS, Siegel DM, Skelsey MK, Peck GL, Hren C, Gorman C, Frumento T, Jansen B, Yao Z, Rock J, Knezevich SR, Cockerell CJ.

Dermatol Online J. 2019 Jun 6;25(6). pii: 13030/qt452297hk.

4.

Impact on clinical practice of a non-invasive gene expression melanoma rule-out test: 12-month follow-up of negative test results and utility data from a large US registry study.

Ferris LK, Rigel DS, Siegel DM, Skelsey MK, Peck GL, Hren C, Gorman C, Frumento T, Jansen B, Yao Z, Rock J, Knezevich SR, Cockerell CJ.

Dermatol Online J. 2019 May 15;25(5). pii: 13030/qt61w6h7mn. Erratum in: Dermatol Online J. 2019 Jun 06;25(6):.

5.

Thick Melanoma Is Associated with Low Melanoma Knowledge and Low Perceived Health Competence, but Not Delays in Care.

Zhang S, Liu R, Siripong N, Kirkwood J, Holtzman MP, Davar D, Najjar Y, Marshall K, Cullison SJ, Houston NA, Switzer G, Ferris LK.

J Am Acad Dermatol. 2019 May 28. pii: S0190-9622(19)30872-2. doi: 10.1016/j.jaad.2019.05.068. [Epub ahead of print] No abstract available.

PMID:
31150702
6.

Benefits to patient care of electronically capturing patient-reported outcomes in dermatology.

Secrest AM, Chren MM, Hopkins ZH, Chen SC, Ferris LK, Hess R.

Br J Dermatol. 2019 Oct;181(4):826-827. doi: 10.1111/bjd.18027. Epub 2019 Jul 15. No abstract available.

PMID:
31017651
7.

Efficacy and safety of guselkumab, administered with a novel patient-controlled injector (One-Press), for moderate-to-severe psoriasis: results from the phase 3 ORION study.

Ferris LK, Ott E, Jiang J, Hong HC, Li S, Han C, Baran W.

J Dermatolog Treat. 2020 Mar;31(2):152-159. doi: 10.1080/09546634.2019.1587145. Epub 2019 Mar 19.

PMID:
30887876
8.

Noninvasive Analysis of High-Risk Driver Mutations and Gene Expression Profiles in Primary Cutaneous Melanoma.

Ferris LK, Moy RL, Gerami P, Sligh JE, Jansen B, Yao Z, Cockerell CJ.

J Invest Dermatol. 2019 May;139(5):1127-1134. doi: 10.1016/j.jid.2018.10.041. Epub 2018 Nov 27.

9.

Risk of Subsequent Cutaneous Melanoma in Moderately Dysplastic Nevi Excisionally Biopsied but With Positive Histologic Margins.

Kim CC, Berry EG, Marchetti MA, Swetter SM, Lim G, Grossman D, Curiel-Lewandrowski C, Chu EY, Ming ME, Zhu K, Brahmbhatt M, Balakrishnan V, Davis MJ, Wolner Z, Fleming N, Ferris LK, Nguyen J, Trofymenko O, Liu Y, Chen SC; Pigmented Lesion Subcommittee, Melanoma Prevention Working Group.

JAMA Dermatol. 2018 Dec 1;154(12):1401-1408. doi: 10.1001/jamadermatol.2018.3359.

10.

Psychosocial impact of skin biopsies in the setting of melanoma screening: a cross-sectional survey.

Matthews NH, Risica PM, Ferris LK, Beatson M, Saul M, Geller AC, Solano F, Kirkwood JM, Weinstock MA.

Br J Dermatol. 2019 Mar;180(3):664-665. doi: 10.1111/bjd.17134. Epub 2018 Oct 23. No abstract available.

PMID:
30183068
11.

Performance of Dermatology Physician Assistants-Reply.

Ferris LK, Anderson AM, Matsumoto M.

JAMA Dermatol. 2018 Oct 1;154(10):1229-1230. doi: 10.1001/jamadermatol.2018.2696. No abstract available.

PMID:
30046838
12.

Real-world performance and utility of a noninvasive gene expression assay to evaluate melanoma risk in pigmented lesions.

Ferris LK, Gerami P, Skelsey MK, Peck G, Hren C, Gorman C, Frumento T, Siegel DM.

Melanoma Res. 2018 Oct;28(5):478-482. doi: 10.1097/CMR.0000000000000478.

PMID:
30004988
13.

Cost-Effectiveness of Melanoma Screening in Inflammatory Bowel Disease.

Anderson AJM, Ferris LK, Binion DG, Smith KJ.

Dig Dis Sci. 2018 Oct;63(10):2564-2572. doi: 10.1007/s10620-018-5141-1. Epub 2018 Jun 13.

PMID:
29948569
14.

Psychosocial consequences of skin cancer screening.

Risica PM, Matthews NH, Dionne L, Mello J, Ferris LK, Saul M, Geller AC, Solano F, Kirkwood JM, Weinstock MA.

Prev Med Rep. 2018 Apr 17;10:310-316. doi: 10.1016/j.pmedr.2018.04.011. eCollection 2018 Jun.

15.

Low Rates of Dermatologic Care and Skin Cancer Screening Among Inflammatory Bowel Disease Patients.

Anderson A, Ferris LK, Click B, Ramos-Rivers C, Koutroubakis IE, Hashash JG, Dunn M, Barrie A, Schwartz M, Regueiro M, Binion DG.

Dig Dis Sci. 2018 Oct;63(10):2729-2739. doi: 10.1007/s10620-018-5056-x. Epub 2018 Apr 30.

PMID:
29713987
16.

Accuracy of Skin Cancer Diagnosis by Physician Assistants Compared With Dermatologists in a Large Health Care System.

Anderson AM, Matsumoto M, Saul MI, Secrest AM, Ferris LK.

JAMA Dermatol. 2018 May 1;154(5):569-573. doi: 10.1001/jamadermatol.2018.0212. Erratum in: JAMA Dermatol. 2018 Jun 1;154(6):739.

17.

Evaluation of Biodistribution of Sulforaphane after Administration of Oral Broccoli Sprout Extract in Melanoma Patients with Multiple Atypical Nevi.

Tahata S, Singh SV, Lin Y, Hahm ER, Beumer JH, Christner SM, Rao UN, Sander C, Tarhini AA, Tawbi H, Ferris LK, Wilson M, Rose A, Dietz CM, Hughes E, Fahey JW, Leachman SA, Cassidy PB, Butterfield LH, Zarour HM, Kirkwood JM.

Cancer Prev Res (Phila). 2018 Jul;11(7):429-438. doi: 10.1158/1940-6207.CAPR-17-0268. Epub 2018 Apr 24.

18.

The Value of Behavioral Counseling for Skin Cancer Prevention: Actions We Can Take Now and Guidance for the Future.

Ferris LK.

JAMA Oncol. 2018 May 1;4(5):630-632. doi: 10.1001/jamaoncol.2018.0469. No abstract available.

PMID:
29558534
19.

Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients.

Zager JS, Gastman BR, Leachman S, Gonzalez RC, Fleming MD, Ferris LK, Ho J, Miller AR, Cook RW, Covington KR, Meldi-Plasseraud K, Middlebrook B, Kaminester LH, Greisinger A, Estrada SI, Pariser DM, Cranmer LD, Messina JL, Vetto JT, Wayne JD, Delman KA, Lawson DH, Gerami P.

BMC Cancer. 2018 Feb 5;18(1):130. doi: 10.1186/s12885-018-4016-3.

20.

Risk Factors for Hidradenitis Suppurativa in Patients with Inflammatory Bowel Disease.

Lukach AJ, Saul MI, Ferris LK, Swoger JM.

Dig Dis Sci. 2018 Mar;63(3):755-760. doi: 10.1007/s10620-018-4919-5. Epub 2018 Jan 22.

PMID:
29357084
21.

Estimating the cost of skin cancer detection by dermatology providers in a large health care system.

Matsumoto M, Secrest A, Anderson A, Saul MI, Ho J, Kirkwood JM, Ferris LK.

J Am Acad Dermatol. 2018 Apr;78(4):701-709.e1. doi: 10.1016/j.jaad.2017.11.033. Epub 2017 Nov 24.

22.

Topical electrophilic nitro-fatty acids potentiate cutaneous inflammation.

Mathers AR, Carey CD, Killeen ME, Salvatore SR, Ferris LK, Freeman BA, Schopfer FJ, Falo LD Jr.

Free Radic Biol Med. 2018 Feb 1;115:31-42. doi: 10.1016/j.freeradbiomed.2017.11.009. Epub 2017 Nov 10.

23.

Smartphone-Based Applications for Skin Monitoring and Melanoma Detection.

Chao E, Meenan CK, Ferris LK.

Dermatol Clin. 2017 Oct;35(4):551-557. doi: 10.1016/j.det.2017.06.014. Epub 2017 Aug 9. Review.

PMID:
28886812
24.

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study.

Bagel J, Duffin KC, Moore A, Ferris LK, Siu K, Steadman J, Kianifard F, Nyirady J, Lebwohl M.

J Am Acad Dermatol. 2017 Oct;77(4):667-674. doi: 10.1016/j.jaad.2017.05.033. Epub 2017 Aug 2.

25.

Skin cancer screening: recommendations for data-driven screening guidelines and a review of the US Preventive Services Task Force controversy.

Johnson MM, Leachman SA, Aspinwall LG, Cranmer LD, Curiel-Lewandrowski C, Sondak VK, Stemwedel CE, Swetter SM, Vetto J, Bowles T, Dellavalle RP, Geskin LJ, Grossman D, Grossmann KF, Hawkes JE, Jeter JM, Kim CC, Kirkwood JM, Mangold AR, Meyskens F, Ming ME, Nelson KC, Piepkorn M, Pollack BP, Robinson JK, Sober AJ, Trotter S, Venna SS, Agarwala S, Alani R, Averbook B, Bar A, Becevic M, Box N, E Carson W 3rd, Cassidy PB, Chen SC, Chu EY, Ellis DL, Ferris LK, Fisher DE, Kendra K, Lawson DH, Leming PD, Margolin KA, Markovic S, Martini MC, Miller D, Sahni D, Sharfman WH, Stein J, Stratigos AJ, Tarhini A, Taylor MH, Wisco OJ, Wong MK.

Melanoma Manag. 2017 Mar;4(1):13-37. doi: 10.2217/mmt-2016-0022. Epub 2017 Mar 1. Review.

26.

BAP1 regulates IP3R3-mediated Ca2+ flux to mitochondria suppressing cell transformation.

Bononi A, Giorgi C, Patergnani S, Larson D, Verbruggen K, Tanji M, Pellegrini L, Signorato V, Olivetto F, Pastorino S, Nasu M, Napolitano A, Gaudino G, Morris P, Sakamoto G, Ferris LK, Danese A, Raimondi A, Tacchetti C, Kuchay S, Pass HI, Affar EB, Yang H, Pinton P, Carbone M.

Nature. 2017 Jun 22;546(7659):549-553. doi: 10.1038/nature22798. Epub 2017 Jun 14.

27.

Extension of ustekinumab maintenance dosing interval in moderate-to-severe psoriasis: results of a phase IIIb, randomized, double-blinded, active-controlled, multicentre study (PSTELLAR).

Blauvelt A, Ferris LK, Yamauchi PS, Qureshi A, Leonardi CL, Farahi K, Fakharzadeh S, Hsu MC, Li S, Chevrier M, Smith K, Goyal K, Chen Y, Muñoz-Elías EJ, Callis Duffin K.

Br J Dermatol. 2017 Dec;177(6):1552-1561. doi: 10.1111/bjd.15722. Epub 2017 Nov 16.

PMID:
28600818
28.

Utility of a Noninvasive 2-Gene Molecular Assay for Cutaneous Melanoma and Effect on the Decision to Biopsy.

Ferris LK, Jansen B, Ho J, Busam KJ, Gross K, Hansen DD, Alsobrook JP 2nd, Yao Z, Peck GL, Gerami P.

JAMA Dermatol. 2017 Jul 1;153(7):675-680. doi: 10.1001/jamadermatol.2017.0473.

29.

Nonmelanoma skin cancer and risk of all-cause and cancer-related mortality: a systematic review.

Barton V, Armeson K, Hampras S, Ferris LK, Visvanathan K, Rollison D, Alberg AJ.

Arch Dermatol Res. 2017 May;309(4):243-251. doi: 10.1007/s00403-017-1724-5. Epub 2017 Mar 11. Review.

30.

A Large Skin Cancer Screening Quality Initiative: Description and First-Year Outcomes.

Ferris LK, Saul MI, Lin Y, Ding F, Weinstock MA, Geller AC, Yuan JM, Neuren E, Maddukuri S, Solano FX, Kirkwood JM.

JAMA Oncol. 2017 Aug 1;3(8):1112-1115. doi: 10.1001/jamaoncol.2016.6779.

31.

Tattoo Artists' Approach to Melanocytic Nevi.

Mori WS, Peters KV, Ferris LK, Patton TJ.

JAMA Dermatol. 2017 Apr 1;153(4):328-330. doi: 10.1001/jamadermatol.2016.5243. No abstract available.

PMID:
28114636
32.

Identification of high-risk cutaneous melanoma tumors is improved when combining the online American Joint Committee on Cancer Individualized Melanoma Patient Outcome Prediction Tool with a 31-gene expression profile-based classification.

Ferris LK, Farberg AS, Middlebrook B, Johnson CE, Lassen N, Oelschlager KM, Maetzold DJ, Cook RW, Rigel DS, Gerami P.

J Am Acad Dermatol. 2017 May;76(5):818-825.e3. doi: 10.1016/j.jaad.2016.11.051. Epub 2017 Jan 19.

33.

A cross-sectional study of indoor tanning use among patients seeking skin cancer screening.

Andrulonis R, Secrest AM, Patton TJ, Grandinetti LM, Ferris LK.

J Am Acad Dermatol. 2017 Jan;76(1):164-165. doi: 10.1016/j.jaad.2016.07.055. No abstract available.

PMID:
27986143
34.

Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data.

Strober B, Leonardi C, Papp KA, Mrowietz U, Ohtsuki M, Bissonnette R, Ferris LK, Paul C, Lebwohl M, Braun DK, Mallbris L, Wilhelm S, Xu W, Ljungberg A, Acharya N, Reich K.

J Am Acad Dermatol. 2017 Mar;76(3):432-440.e17. doi: 10.1016/j.jaad.2016.09.026. Epub 2016 Nov 23.

35.

Dysplastic nevi with severe atypia: Long-term outcomes in patients with and without re-excision.

Engeln K, Peters K, Ho J, Jedrych J, Winger D, Ferris LK, Patton T.

J Am Acad Dermatol. 2017 Feb;76(2):244-249. doi: 10.1016/j.jaad.2016.08.054. Epub 2016 Nov 9.

PMID:
27838051
36.

Development and validation of a noninvasive 2-gene molecular assay for cutaneous melanoma.

Gerami P, Yao Z, Polsky D, Jansen B, Busam K, Ho J, Martini M, Ferris LK.

J Am Acad Dermatol. 2017 Jan;76(1):114-120.e2. doi: 10.1016/j.jaad.2016.07.038. Epub 2016 Oct 1.

37.

Myeloid-derived suppressor cells are elevated in patients with psoriasis and produce various molecules.

Ilkovitch D, Ferris LK.

Mol Med Rep. 2016 Oct;14(4):3935-40. doi: 10.3892/mmr.2016.5685. Epub 2016 Aug 26.

38.
39.
40.

A pragmatic approach to melanoma screening in collaboration with primary care providers.

Anderson AJ, Kirkwood JM, Ferris LK.

Cutis. 2016 Jun;97(6):382-3. No abstract available.

PMID:
27416080
41.

Downstream consequences of melanoma screening in a community practice setting: First results.

Weinstock MA, Ferris LK, Saul MI, Geller AC, Risica PM, Siegel JA, Solano FX, Kirkwood JM.

Cancer. 2016 Oct 15;122(20):3152-3156. doi: 10.1002/cncr.30177. Epub 2016 Jul 8.

42.

Patient Preferences During Skin Cancer Screening Examination.

Houston NA, Secrest AM, Harris RJ, Mori WS, Eliason MJ, Phillips CM, Ferris LK.

JAMA Dermatol. 2016 Sep 1;152(9):1052-4. doi: 10.1001/jamadermatol.2016.1005. No abstract available.

PMID:
27166873
43.

Personal Burden of Isotretinoin Therapy and Willingness to Pay for Electronic Follow-up Visits.

Mori WS, Houston N, Moreau JF, Prevost N, Gehris RP, Ferris LK, Patton TJ.

JAMA Dermatol. 2016 Mar;152(3):338-40. doi: 10.1001/jamadermatol.2015.4763. No abstract available.

PMID:
26720269
44.

Computer-aided classification of melanocytic lesions using dermoscopic images.

Ferris LK, Harkes JA, Gilbert B, Winger DG, Golubets K, Akilov O, Satyanarayanan M.

J Am Acad Dermatol. 2015 Nov;73(5):769-76. doi: 10.1016/j.jaad.2015.07.028. Epub 2015 Sep 19.

PMID:
26386631
45.

Prevalence and impact of health-related internet and smartphone use among dermatology patients.

Wolf JA, Moreau JF, Patton TJ, Winger DG, Ferris LK.

Cutis. 2015 Jun;95(6):323-8.

PMID:
26125208
46.

Indoor Tanning, Skin Cancer and the Young Female Patient: A Review of the Literature.

Friedman B, English JC 3rd, Ferris LK.

J Pediatr Adolesc Gynecol. 2015 Aug;28(4):275-83. doi: 10.1016/j.jpag.2014.07.015. Epub 2014 Aug 19. Review.

PMID:
26119073
47.

We Pledge to Change iPLEDGE.

Pierson JC, Ferris LK, Schwarz EB.

JAMA Dermatol. 2015 Jul;151(7):701-2. doi: 10.1001/jamadermatol.2015.0736. No abstract available.

PMID:
25853235
48.

Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial.

Krueger JG, Ferris LK, Menter A, Wagner F, White A, Visvanathan S, Lalovic B, Aslanyan S, Wang EE, Hall D, Solinger A, Padula S, Scholl P.

J Allergy Clin Immunol. 2015 Jul;136(1):116-124.e7. doi: 10.1016/j.jaci.2015.01.018. Epub 2015 Mar 11.

PMID:
25769911
49.

Gene expression profiling for molecular staging of cutaneous melanoma in patients undergoing sentinel lymph node biopsy.

Gerami P, Cook RW, Russell MC, Wilkinson J, Amaria RN, Gonzalez R, Lyle S, Jackson GL, Greisinger AJ, Johnson CE, Oelschlager KM, Stone JF, Maetzold DJ, Ferris LK, Wayne JD, Cooper C, Obregon R, Delman KA, Lawson D.

J Am Acad Dermatol. 2015 May;72(5):780-5.e3. doi: 10.1016/j.jaad.2015.01.009. Epub 2015 Mar 3.

PMID:
25748297
50.

Promoting safe use of isotretinoin by increasing contraceptive knowledge.

Werner CA, Papic MJ, Ferris LK, Schwarz EB.

JAMA Dermatol. 2015 Apr;151(4):389-93. doi: 10.1001/jamadermatol.2014.4171.

PMID:
25650743

Supplemental Content

Loading ...
Support Center